3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. (September 2015) - Kasahara, K.; Kiura, K.; Nogami, N.; Takayama, K.; Takiguchi, Y.; Hirashima, T.; Aoe, K.; Hayashi, H.; Saka, H.; Takahashi, K.; Imamura, F.; Oizumi, S.; et al.